Month: June 2026

Introduction and Objective: Despite being a major contributor to reduced life expectancy in type 1 diabetes (T1D), cardiovascular disease (CVD) and T1D-associated cardiomyopathy remain poorly understood. Insulin-like growth factor binding protein-7 (IGFBP7), a member of the IGFBPs, was found elevated in serum of patients with heart failure and kidney disease. Clinical studies in patients with […]

Introduction and Objective: Obesity and prediabetes are characterized by abnormal glucagon response to glucose and amino acids (AA). Elevated AA concentrations, seen in these states, are associated with increased risk of type 2 diabetes. The relative contributions of AA, glucose and insulin to glucagon secretion is unknown.Methods: Lean (BMI: 23 ± 0.5 kg/m2, n = […]

Introduction and Objective: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are widely used for type 2 diabetes and reduce hospitalization and cardiovascular death in heart failure with reduced ejection fraction (HFrEF). Ventricular arrhythmias are a major cause of death in HFrEF, but the effect of SGLT2i on arrhythmia risk remains unclear. This systematic review and meta-analysis evaluated whether […]

Introduction and Objective: Proteomics can provide insight into mechanisms linking diabetes to dementia risk. We identified plasma central nervous system (CNS) proteins associated with incident dementia in older adults with diabetes.Methods: We conducted a prospective cohort study of 487 ARIC Study participants with diabetes (age 58-84y, 47% women, 34% Black) in 2005-06. We quantified the […]

Introduction and Objective: Glucagon-like peptide 1 (GLP1) receptor agonists such as semaglutide have made medical weight loss possible, but for many the continued treatment necessary to maintain the weight loss is not sustainable. Reasons include gastrointestinal side effects, loss of lean/muscle mass, need for injections, and high cost. This results in half of the people […]

Introduction and Objective: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were proposed to exert neuroprotective effects. Preliminary data from the EVOKE placebo-controlled phase-3 trials indicate that 2-year oral semaglutide therapy, although improving Alzheimer’s-related biomarkers, did not mitigate disease progression in people with early Alzheimer’s, mostly without type 2 diabetes (T2D). It remains unclear whether GLP-1 RAs […]

Introduction and Objective: The SELECT trial of patients with BMI ≥27 kg/m2 and CVD without diabetes found a 20% reduction in major adverse CV events (MACE) with semaglutide. Proteomic analysis in the STEP 1 trial yielded proteins modulated by semaglutide. For six of these proteins with genetic evidence for causal effects on cardiovascular disease (CVD), […]

Introduction and Objective: In South Carolina (SC), women with or at risk for diabetes often experience a lack of preventive care, fragmented services, and inadequate follow-up. These challenges are further compounded during pregnancy. The Women’s Health Initiative (WHI) a program of Diabetes Free SC (DFSC), was developed to improve diabetes prevention, education, and management for […]

Introduction and Objective: The relative contribution of circulating glucose and insulin concentrations to glucagon secretion in healthy individuals is unknown. We therefore assessed glucagon secretion using [13C9,15N1]-glucagon tracer at varying insulin and glucose concentrations in healthy individuals.Methods: After overnight fast, twelve healthy individuals underwent three separate clamp visits (hypo-, eu-, hyper-glycemia) in random order at […]

Introduction and Objective: A novel fully autonomous microneedle array sensor providing semi-quantitative real-time glucose ranges expressed as three colors (Fig 1), activity and sleep data (Biolinq Incorporated, San Diego, CA) was developed to improve adherence in users with low numeracy burdened by CGM for safety and accuracy.Methods: A trial was conducted at 6 US sites […]